RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
about
Human Cancer Immunotherapy with PD-1/PD-L1 BlockadeOvercoming T cell exhaustion in infection and cancerNew immunotherapies targeting the PD-1 pathwayPD-1 and its ligands are important immune checkpoints in cancerPD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsImmune checkpoint blockade: a common denominator approach to cancer therapyPD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.PD-1 as an immune modulatory receptor.Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation.Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma.Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.Repulsive guidance molecule B inhibits metastasis and is associated with decreased mortality in non-small cell lung cancerEmerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.Programmed death-1 & its ligands: promising targets for cancer immunotherapy.PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation.The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment.Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.Prospects and progress of atezolizumab in non-small cell lung cancer.Co-stimulate or Co-inhibit Regulatory T Cells, Which Side to Go?Potential targeting of B7-H4 for the treatment of cancer.PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load.The safety of anti PD-1 therapeutics for the treatment of melanoma.Immune checkpoint inhibitors for cancer treatment.Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies.Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease.Pembrolizumab (Keytruda)PD-L2 Regulates B-1 Cell Antibody Production against Phosphorylcholine through an IL-5-Dependent Mechanism.PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.Identification and characterization of bovine programmed death-ligand 2.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Programmed cell death ligand 1 as a biomarker in head and neck cancer.Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects.PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.The diverse functions of the PD1 inhibitory pathway.Lung Tissue Injury as an Atypical Response to Nivolumab in Non-Small Cell Lung Cancer.Differential regulation of PD-1 and its ligands in allergic asthma.
P2860
Q26786108-14F7C8E6-F15B-43FE-BFB0-224BC7D5CE54Q26829885-69E9C99F-5CE4-4E97-AAB5-322D0FE0E3CEQ27010018-89162A65-9253-411B-A45D-B344C5E44656Q28069485-F242150D-918D-4982-9707-C27AEDFDA377Q28075712-1F4D3903-FE60-41BD-834B-78388580C47EQ28083981-B4E3A992-9332-46C7-A3BA-A3717F700AA5Q30275174-11D289B5-5665-4159-894A-DDB6EC271B49Q33912075-4557D1D0-5DFD-4F4A-905C-32159C7B4694Q34809019-4B0E61A5-6DA6-47EB-AE21-5F61E06BB5B4Q35681585-D61EA5D8-F270-4B1C-AF64-073405967409Q35681604-CC3568C2-943E-4E69-BE8B-77C0151EBF75Q36106006-2EA23628-5C37-4C05-B492-B87B2C4CC559Q36132761-D0E47136-68C8-47B5-A62C-57ACFAB3DC88Q36998864-02B4456B-510D-4676-8D09-EA4FCE9CA3CCQ37085857-E915E074-599A-4B9D-883A-DAE03C18DD62Q37158481-A0B5B061-02EF-486D-81A1-0512ABB1044DQ38562062-B08C797D-69D0-406A-A613-B0A4237B3BC2Q38622789-9850A82A-A32C-4987-9362-02F1BEBFFF82Q38833182-67BE12CD-5F7C-4E82-9B37-7137F9D17C35Q38870929-F2C9E3F0-DD22-44F3-A59A-5FA3DD75BE62Q38881814-49ECD639-FDF1-4FDA-851B-613FA3039D3CQ38897638-A77E7EDC-C084-4426-9107-D171A739D032Q38930119-EC53F807-E457-4E33-B8E6-3A879FC2ECF2Q38931346-4DAA7568-3FEE-470B-A850-33DC68875CABQ38979801-77DC7396-9697-49EA-99D1-6569CBDA7836Q38988058-17A91556-CD0C-4A9C-A92A-0CB68AECA29AQ38996832-B5EE18AC-462D-47FE-830B-CD7D509C12B8Q38999322-83857F7A-9904-47DF-A24C-BD547ACFFDEEQ39313794-9E8B5A50-AEA2-4783-9C0B-89FA610FBA08Q39615516-09B63709-7C18-45E4-B648-3DE49034E8EBQ40109527-09695C86-C169-4D6E-93C4-E6188BECB78FQ41526004-268AC1BF-63A4-4197-93B9-2D5A2DC626F6Q42217541-647442BC-EB4D-439A-ADBB-01822DFE4264Q47120629-F65AD4EC-4624-41D6-B1B2-1B97DB46DF62Q47122217-3E8F2795-3EB9-4C36-BFD1-02F0087876C3Q47239900-7883759A-BAA2-4932-B65C-DDA5A396470CQ47424027-EA4DB3E5-0A65-4C91-86E7-E5F4B20A1324Q47678849-35B68598-ED36-4DE9-9625-14E5CC8B2091Q47803357-24C49C32-CF5A-4BB0-8FDE-8689DEDB11A1Q48136496-4EDF0440-CA55-4935-869B-F1E6221B01E4
P2860
RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
RGMb is a novel binding partne ...... promotes respiratory tolerance
@ast
RGMb is a novel binding partne ...... promotes respiratory tolerance
@en
RGMb is a novel binding partne ...... romotes respiratory tolerance.
@nl
type
label
RGMb is a novel binding partne ...... promotes respiratory tolerance
@ast
RGMb is a novel binding partne ...... promotes respiratory tolerance
@en
RGMb is a novel binding partne ...... romotes respiratory tolerance.
@nl
prefLabel
RGMb is a novel binding partne ...... promotes respiratory tolerance
@ast
RGMb is a novel binding partne ...... promotes respiratory tolerance
@en
RGMb is a novel binding partne ...... romotes respiratory tolerance.
@nl
P2093
P2860
P356
P1476
RGMb is a novel binding partne ...... promotes respiratory tolerance
@en
P2093
Arlene H Sharpe
Baogong Zhu
Dale T Umetsu
Denis Bedoret
Gordon J Freeman
Loise M Francisco
Rosemarie H DeKruyff
Sanhong Yu
P2860
P304
P356
10.1084/JEM.20130790
P407
P577
2014-04-21T00:00:00Z